Teva Snaps Up Cephalon - Analyst Blog
May 03 2011 - 6:00AM
Zacks
Yet another acquisition deal was announced in the pharma sector
with generic player, Teva Pharmaceutical Industries
Ltd. (TEVA) entering into a definitive agreement with
Cephalon, Inc. (CEPH). Teva intends to acquire
Cephalon for $81.50 per share in cash or $6.8 billion.
Teva Tops Valeant Bid
Cephalon has been in the news over the past few weeks with
Valeant Pharmaceuticals (VRX) expressing an
interest in acquiring the company. Valeant had initially approached
Cephalon in late March with a $73 bid. However, Cephalon rejected
the offer. Teva’s offer price tops Valeant’s offer and represents a
39% premium to Cephalon’s stock price before Valeant’s unsolicited
proposal was announced.
Deal in line with Long-Term Strategy
The Cephalon deal is in line with Teva’s long-term strategy of
expanding and strengthening its branded and specialty pharma
business. Once the acquisition goes through, the combined company’s
branded product portfolio will consist of more than 20 products
representing sales of about $7 billion. While Teva’s branded
portfolio consists of Copaxone (multiple sclerosis), Azilect
(Parkinson’s disease), respiratory and women’s health products,
Cephalon will be bringing with it products like Provigil/Nuvigil
(sleep disorder), Amrix, Actiq and Fentora (for pain management),
and Treanda and Trisenox (oncology).
The acquisition makes sense for Teva which is currently facing
patent challenges for Copaxone. With Copaxone accounting for 20.5%
of total revenues in 2010, the earlier than expected entry of
generic versions of Copaxone would be a major setback for Teva.
Cephalon also has a presence in the generics market following
its April 2010 acquisition of Mepha AG, which specializes in the
marketing of branded and non-branded generics and specialty
products in more than 50 countries. Mepha has a presence mainly in
Europe, the Middle East, Africa, South and Central America and
Asia.
Teva’s pipeline will also be boosted significantly following the
closing of the acquisition. Cephalon has several candidates in its
pipeline including Lupuzor (systemic lupus erythematosus), and
Cinquil (eosinophilic asthma).
Financial Impact
Teva expects to achieve cost synergies of at least $500 million
per annum from the third year following the closing of the deal.
The deal, meanwhile, is expected to be immediately accretive to
earnings. Teva intends to use cash on hand, lines of credit and the
public debt market to finance the deal.
Neutral on Teva
We currently have a Neutral recommendation on Teva, supported by
a Zacks #3 Rank (short-term “Hold” rating). The Cephalon deal,
which is scheduled to close in the third quarter of 2011, will not
only strengthen Teva’s pipeline; it should also help the company
achieve its goal of increasing its branded revenues from $4.6
billion in 2010 to more than $9 billion in 2015.
CEPHALON INC (CEPH): Free Stock Analysis Report
TEVA PHARM ADR (TEVA): Free Stock Analysis Report
Zacks Investment Research
Cephalon (NASDAQ:CEPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cephalon (NASDAQ:CEPH)
Historical Stock Chart
From Jul 2023 to Jul 2024